Browse the evidence

Physical exercise induces white adipose tissue browning through the secretion of myokines such as Irisin, FGF21, and Beta-Aminoisobutyric acid, which upregulate UCP1 and thermogenic genes.

Engage in regular physical exercise to trigger the release of myokines like Irisin and FGF21. These molecules signal your white fat to turn into metabolically active beige fat, increasing your energy expenditure and metabolic efficiency. The specific type of exercise is less important than consistency in triggering these hormonal responses.

Weight loss achieved through primary care interventions, whether pharmacologic or lifestyle-based, significantly attenuates over time, with an average regain of 0.53 kg per six months.

Do not expect your initial weight loss to stick if you stop the intervention. The body fights back against weight loss through hormonal changes. To maintain weight loss, you likely need to continue the intervention (medication or intensive lifestyle support) long-term, rather than treating it as a finite 'course'.

GLP-1 receptor agonists (GLP-1RA) are associated with a disproportionate reporting signal for specific neoplasms, particularly medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and pancreatic neoplasms, whereas overall tumor risk is not significantly increased.

GLP-1 receptor agonists do not increase the overall risk of cancer, but they are associated with specific, high-magnitude signals for medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and pancreatic neoplasms. Clinicians should maintain vigilance, particularly when combining GLP-1RA with DPP4 inhibitors, which may further increase reporting rates for these specific tumors. The benefits of GLP-1RA for cardiovascular and metabolic health remain significant, but patients with a history of MTC or pancreatitis should be carefully evaluated.

High-glycemic load carbohydrates drive obesity through calorie-independent hormonal mechanisms (specifically insulin-mediated fat storage and reduced energy expenditure) rather than solely through excess caloric intake.

Focus on reducing the glycemic load of your diet by minimizing refined carbohydrates, sugars, and processed grains. This approach addresses the hormonal drivers of fat storage (insulin) and energy partitioning, rather than relying solely on calorie restriction which may trigger metabolic slowdown and hunger.

Mendelian randomization studies suggest that genetic predisposition to MASLD via impaired VLDL secretion (PNPLA3, TM6SF2) may lower plasma lipids and potentially reduce coronary artery disease risk, whereas other MASLD genes show weak or no association with CAD.

This is a mechanistic insight rather than a direct intervention. It suggests that the way some people develop liver fat (by not secreting VLDL efficiently) might paradoxically protect them from heart disease. This highlights the complexity of the liver-heart axis.

Exposure to environmental obesogens (e.g., BPA, PFAS, pesticides) during critical developmental windows programs long-term metabolic dysfunction by hijacking redox signaling (ROS) and endocrine pathways, leading to increased adiposity and insulin resistance later in life.

To mitigate the impact of obesogens, prioritize reducing exposure to environmental chemicals that disrupt hormonal and redox signaling. This includes choosing fresh foods over ultra-processed items (which may contain obesogenic additives or packaging leachates), filtering drinking water, and minimizing the use of plastics (especially for heating food) and harsh household cleaners. While diet and exercise remain important, recognizing the role of environmental factors suggests that reducing exposure to these chemicals is a critical, often overlooked component of obesity prevention.

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) is associated with a low incidence (1.18%) of psychiatric adverse events, including depression, anxiety, and suicidal ideation, with a small but significant number of fatal outcomes.

If you are taking semaglutide, liraglutide, or tirzepatide, be aware that mood changes like depression, anxiety, or suicidal thoughts are possible, though uncommon (approx 1%). Monitor your mental health closely. If you experience these symptoms, report them to your doctor immediately. Do not suffer in silence; early reporting helps manage safety risks.

GLP-1 receptor agonist treatment is associated with a statistically significant increase in specific psychiatric adverse events, including nervousness, stress, eating disorders, insomnia, binge eating, fear of eating, and self-induced vomiting, with onset typically occurring within the first 30 days.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that psychiatric side effects are a recognized risk, not just a rare anecdote. Symptoms like nervousness, stress, insomnia, and changes in eating behavior (such as bingeing or fear of eating) can start within the first month of treatment. Because these reports are disproportionately high in the database, you should proactively monitor your mental health and mood, especially if you have a history of anxiety or eating disorders, and report any new or worsening symptoms to your prescriber immediately.

Rapid weight loss induced by GLP-1 receptor agonists (e.g., semaglutide) causes significant facial volume depletion and skin laxity, resulting in an aged appearance termed 'Ozempic face'.

If you are taking Ozempic or similar drugs, be aware that rapid weight loss can hollow out your face and make you look older. This is a known side effect. If it happens, consult a plastic surgeon about fillers or skin tightening to restore volume.

Sex hormone-binding globulin (SHBG) acts as a potential mediator in the causal relationship between higher cardiorespiratory fitness and lower type 2 diabetes risk.

Higher fitness is linked to higher levels of SHBG, which is known to protect against type 2 diabetes. This suggests that improving fitness may work partly by optimizing your hormone binding profiles.

Semaglutide treatment reduces plasma levels of FABP4 and modulates neutrophil phenotype (increasing CD88, reducing CD11b-mediated adhesion), thereby attenuating prothrombotic and atherosclerotic mechanisms.

For patients with Type 2 Diabetes and obesity who are not controlled on oral medications, Semaglutide (0.5-1.0 mg weekly) not only aids weight loss but may also reduce specific cardiovascular risk markers like FABP4 and improve neutrophil behavior, potentially lowering atherosclerosis risk. This benefit is observed after 6 months of treatment.

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

GLP-1 receptor agonists (specifically liraglutide and exendin-4) inhibit cancer progression and proliferation in various malignancies (breast, prostate, pancreatic, ovarian, colon, liver) through mechanisms including apoptosis induction, cell cycle arrest, and inhibition of signaling pathways like PI3K/Akt/mTOR and MAPK.

This paper highlights that while semaglutide (Ozempic/Wegovy) has mixed signals regarding cancer risk in humans, other GLP-1 agonists like liraglutide and exendin-4 have demonstrated anti-cancer effects in laboratory and animal studies. For patients, this underscores the importance of discussing specific drug risks with a doctor, especially those with a history of cancer, as the effect is not uniform across all drugs in this class.

The appetite-suppressing effects of GLP-1 analogs attenuate during the weight maintenance phase, suggesting that the biological drive to lose weight diminishes once a new homeostatic fat mass is reached.

As you reach your target weight, the strong appetite suppression from GLP-1 medications may lessen. This is a normal physiological response as your body adjusts to its new weight. Continued monitoring and potentially lifestyle adjustments may be needed to maintain weight loss.

For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.

If you are taking Semaglutide and experiencing intolerable gastrointestinal side effects, discuss with your doctor whether a lower dose (e.g., 0.5mg) might be sufficient to manage your condition with fewer side effects, as higher doses (1mg) are associated with a higher risk of these reactions.

The protective association between plant-based diets and weight loss is weaker or absent in individuals with existing obesity compared to those with normal or overweight status.

If you have obesity, you may find weight loss more challenging with plant-based diets due to metabolic factors like insulin resistance. However, focusing on healthful plant foods remains important for overall health and may still support weight management, even if the effect is less pronounced than in non-obese individuals.

GLP-1 receptor agonists are associated with a rapid worsening of diabetic retinopathy, particularly in patients with a history of retinopathy and those using insulin, likely due to rapid glycemic improvement.

If you have diabetes and are starting a GLP-1 medication, ensure you have regular eye exams. If you already have eye problems, your doctor may monitor you more closely, as rapid blood sugar improvement can temporarily worsen vision.

A higher polygenic score for BMI is associated with lower weight loss following bariatric surgery, although the effect size is modest and attenuates in sensitivity analyses.

If you are considering bariatric surgery, having a high genetic risk for obesity might mean you lose slightly less weight than someone with low genetic risk. However, the surgery is still very effective. You may need to be more vigilant with lifestyle changes or consider adjunct therapies like GLP-1 RAs to maintain your results.

Inhibitors of hepatic lipogenesis (including ACLY, ACC, FAS, SCD1, and DGAT2 inhibitors) reduce liver fat content in MASLD, but some (like ACC inhibitors) may increase serum triglycerides, necessitating combination therapies (e.g., ACC + DGAT2 inhibitors) to mitigate adverse lipid effects.

Several new drugs target the liver's fat-making enzymes (like ACC and FAS). While they reduce liver fat, some can raise blood triglycerides. To avoid this, doctors may combine an ACC inhibitor with a DGAT2 inhibitor. These are still largely in clinical trials and are not yet first-line treatments compared to GLP-1 agonists.

SGLT2 inhibitors reduce hepatic lipid content and liver enzymes in patients with MASLD and Type 2 Diabetes, but histological evidence for treating MASH is still required.

If you have diabetes and fatty liver, SGLT2 inhibitors (like dapagliflozin) are a good option to lower liver fat and enzymes. They work by changing how your body handles sugar and fat. However, they are not yet proven to reverse the scarring of MASH, so they are part of a broader management strategy.

The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.

This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.

GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.

GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.